ZYME:NASDAQ
Zymeworks Inc
26,06 $
arrow_downward
-1,62%(-0,43) 1D
1 қаз., 10:06:20 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ZYME...
Open
26,44 $
High
26,56 $
Low
26,01 $
Mkt. cap
1,85 млрд
Avg. vol.
835,22 м.
Volume
20,22 мың
52-wk high
31,34 $
52-wk low
16,00 $
EPS
-2,01 $
Beta
1,19
Shares outstanding
70,96 млн
No. of employees
231
Open
26,44 $
High
26,56 $
Low
26,01 $
Mkt. cap
1,85 млрд
Avg. vol.
835,22 м.
Volume
20,22 мың
52-wk high
31,34 $
52-wk low
16,00 $
EPS
-2,01 $
Beta
1,19
Shares outstanding
70,96 млн
No. of employees
231
News stories
From web sources and news partners
GuruFocus
·
1 күн бұрын
ZYME Maintained by Citigroup -- Price Target Raised to $39.00
MarketBeat
·
1 күн бұрын
Zymeworks (NASDAQ:ZYME) Stock Rated "Buy" in New Coverage at TD Cowen
Investing.com
·
2 күн бұрын
Zymeworks stock rating maintained at outperform by Citizens
Profile
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
About Zymeworks Inc
CEOKenneth Galbraith
Employees231
Founded2003
HeadquartersВанкувер, Британдық Колумбия, Канада
Sector-
Websitezymeworks.com